Feasibility of magnetic resonance guided radiotherapy for the treatment of bladder cancer.

Whole bladder magnetic resonance image-guided radiotherapy using the 1.5 Telsa MR-linac is feasible. Full online adaptive planning workflow based on the anatomy seen at each fraction was performed. This was delivered within 45 min. Intra-fraction bladder filling did not compromise target coverage. Patients reported acceptable tolerance of treatment.
Competing Interests: The Royal Marsden Hospital and the Institute of Cancer Research are members of the Elekta MR-linac Consortium, which aims to coordinate international collaborative research relating to the Elekta Unity (MR-linac). Elekta (Elekta AB, Stockholm, Sweden) and Philips (Philips, Best, Netherlands) are commercial members of the MR-linac Consortium. Elekta financially supports consortium member institutions with research funding, education, and travel costs for consortium meetings. No commercial financial support was received from any organisation for the submitted work. AH, IH, AD, HB, LB, JC, CC, TH, RL, DM, HM, AM, JM, GS, and SN, have no other conflicts to disclose. HM also reports grant funding from a National Institute for Health Research and Health Education England (NIHR & HEE), Senior Clinical Lecturer award. TM also reports grant from Lister Institute of Preventive Medicine, outside the submitted work. EH is supported by a Cancer Research UK Centres Network Accelerator Award Grant (A21993) to the ART-NET consortium, other grants from Cancer Research UK during the conduct of the study; grants from Accuray Inc., grants from Varian Medical Systems Inc., outside the submitted work. UO also reports grants from Cancer Research UK. RH also reports non-financial support from Janssen, grants and personal fees from MSD, personal fees from Bristol Myers Squibb, grants from Cancer Research UK, other from Nektar Therapeutics, personal fees and non-financial support from Roche outside the submitted work. SH also reports non-financial support from Merck Sharp & Dohme (MSD), personal fees and non-financial support from Roche outside the submitted work.
(© 2020 The Authors.)